A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer - Wikidata - awgldk - TriplyDB

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer

http://www.wikidata.org/entity/Q33395544

about

Targeted drugs in small-cell lung cancer Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Bcl-2 antagonists: a proof of concept for CLL therapy Genomic profiling of small-cell lung cancer: the era of targeted therapies Targeting BCL2-Proteins for the Treatment of Solid Tumours The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics Why anti-Bcl-2 clinical trials fail: a solution Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy Small cell lung cancer: therapies and targets A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.Targeting protein-protein interactions as an anticancer strategy Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.Chemotherapy for small cell lung cancer: a comprehensive review Small cell lung cancer: will recent progress lead to improved outcomes?Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo.Novel therapeutic approaches for small cell lung cancer: the future has arrived Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo.How to unleash mitochondrial apoptotic blockades to kill cancers?mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.Apoptosis-modulating drugs for improved cancer therapy.That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.Harnessing system models of cell death signalling for cytotoxic chemotherapy: towards personalised medicine approaches?Advances in pharmacotherapy of small cell lung cancer.Obatoclax induces Beclin 1- and ATG5-dependent apoptosis and autophagy in adenoid cystic carcinoma cells.A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.Obatoclax induces G1/G0-phase arrest via p38/p21(waf1/Cip1) signaling pathway in human esophageal cancer cells.Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis.Association of anti-apoptotic Mcl-1L isoform expression with radioresistance of oral squamous carcinoma cells.Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors.Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.Why do BCL-2 inhibitors work and where should we use them in the clinic?Second-line treatments of small-cell lung cancers.Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression.Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma.Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy.Advanced small cell lung cancer (SCLC): new challenges and new expectations.

P2860

Q26767017-9771B332-4078-4031-80FF-7D934E777021 Q26771601-0DB6477C-3F07-4CF3-9DA8-F524C537446F Q26823996-C9042440-735F-4A22-BC3B-63824FD697C8 Q26826915-4C5C5957-AF24-401E-8155-62F1C05FF5A1 Q26853686-9311A49F-6696-4233-A7CD-D7A042670B9E Q27010154-4E00A49A-D309-4187-9D07-4A2B73CF72AB Q33758493-B5F1A10E-C9D6-44D1-8D3A-37F29D64EC6D Q34004454-FE1CDEA5-6ED3-4F22-8134-986E0CDE082F Q34250859-17C34F14-9652-44CE-A3C3-9CEBABBF7A4D Q34294097-93F6BBCA-460A-4A8B-B164-B4798761FE0E Q34347892-4836174E-5C7D-4910-B6B2-157A3FE08DB4 Q34977383-D95FE81D-C7F8-45F5-9D02-76F810B7DAA0 Q35212727-2CD5B3C7-F85A-4348-923C-5D7B5F669474 Q35569379-52A3259E-90E7-42D4-89C3-EAE0A78B474D Q35836257-0232B2AC-4008-49B2-BF3D-D45FEAC78235 Q35987399-4FBD4FB6-35BA-4860-9C27-CC20A9FEAC2B Q36084288-F19D85F0-6791-4A5B-AC3F-56DE57497B1A Q36337960-2DEE4587-A465-4680-A842-06364FA21665 Q36601134-3005682C-2285-46B0-ACFA-367EFFC5DFD3 Q37412314-27CFEBAC-606E-45D4-A2DA-B3DDC336BE32 Q37587294-16F7BF9D-F07F-4F9B-AF27-1CBD057C1346 Q37680565-33F37045-0A6F-4D81-9815-D0C1313A7954 Q38005914-0E6FA8D6-8438-414D-98BF-A9BD8FB42790 Q38104439-0C9E0C99-6DD6-402C-AB5B-2B23DBAE2CC9 Q38183302-17C34247-1990-46CB-8F5B-7A6959D87A92 Q38254295-12AA8967-6A90-4EA0-BAE9-F00456A165D9 Q38931618-5C7BBEEC-D924-4BA3-9CA2-B829E3C559C4 Q38947009-3838DD19-A010-48D5-9142-A764880D633E Q38999607-0DF23A6D-6225-453A-AA27-717D79CC54BA Q39493955-A06F95E2-D86A-4966-AC77-E60E8D9602BA Q41531941-339C0216-160B-4C93-8089-D625DD150B44 Q42061450-7D13D661-ACDC-4888-8F30-CD0746B48E65 Q42316815-DB62A8B7-ED17-40C9-BBCD-0E4248E7EA49 Q47159040-082DB3CC-A56D-4736-9374-36368DDFBB14 Q47789861-804F9743-EE7E-44A3-9C2B-30BB758C6805 Q47941645-63517DCC-A587-434A-936C-D41D5E3D4118 Q50897221-EB7AE56C-3D40-4442-812C-C0031E689D45 Q51746852-7C87C9B4-02AE-4E05-A32B-1112DE3B0EA6 Q54977232-02C69352-6C8A-4EC9-85A6-6BA9EA251F46

P2860

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer

http://www.wikidata.org/entity/Q33395544

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A phase II study of obatoclax ...... elapsed small cell lung cancer

@ast

A phase II study of obatoclax ...... elapsed small cell lung cancer

@en

type

label

A phase II study of obatoclax ...... elapsed small cell lung cancer

@ast

A phase II study of obatoclax ...... elapsed small cell lung cancer

@en

prefLabel

A phase II study of obatoclax ...... elapsed small cell lung cancer

@ast

A phase II study of obatoclax ...... elapsed small cell lung cancer

@en

P1433

Q33395544-1E04AF13-683C-4A72-A993-874B4342B64C

P1476

Q33395544-F49D72B3-4585-41FE-955D-12E4F8ED421C

P2093

Q33395544-2090B4B5-B8B9-4EFB-9FAE-7A387918452C

Q33395544-331C2C73-21BE-49E5-A27E-43FC9D189DBF

Q33395544-4F85D7FC-01EC-4E82-9AAE-9C67F373CBB5

Q33395544-65F4AAC0-EC0F-414C-BC83-F7621C908A06

Q33395544-67500D58-B6FC-4EFF-B227-9319C02786EA

Q33395544-73E506FB-F938-4662-8BB6-86E5C5B57A51

Q33395544-7F76951F-7010-487E-943A-02DBAA49EE25

Q33395544-85EC8E1F-6D39-480C-BD3A-A22BE9D1AE7F

Q33395544-90EFF8FB-CBCA-4260-9F26-B4773EE19E3E

Q33395544-9EAA00F5-7D34-469A-A2F6-F24B01CE7E94

P2860

Q33395544-2841AC7B-81C2-456A-BC2A-2093D837E554

Q33395544-38631907-54BD-4A7A-BB0B-6061159F29A1

Q33395544-55ECC6F0-BCB5-47AF-AE9B-B24F1D43DA05

Q33395544-5FA07DFC-9CB2-409E-B1AD-64467A3F6368

Q33395544-67035ECA-3E5D-46FA-BBE0-C661A442E5E7

Q33395544-79A159C4-B57D-4110-A726-9420E9C3F6AD

Q33395544-8530DDB3-4AD1-4C76-8534-81DBBA6A31BA

Q33395544-8D943CAB-2B29-4CED-85D9-FBE6DC724A96

Q33395544-8E106E1D-FCE1-4C2F-9559-456B3BA8CD93

Q33395544-94B830B8-23F5-4954-95E7-EE55B2DB18AA

P304

Q33395544-27D83F48-A677-4ACB-BB37-76D8787271E8

P31

Q33395544-EC3D215F-8035-4DA8-8D06-E5EFD78A58AB

P356

Q33395544-2EAF06E6-5FBF-4F30-829D-5ECB4E56024A

P433

Q33395544-3C307526-5DCF-4A1A-BA60-D2A280AFF3CD

P478

Q33395544-237B0341-0DDB-4BCA-BE31-BD2E3B873D25

P50

Q33395544-CD77D8C3-9127-487E-B6FA-2F8529CA8312

Q33395544-D3B9470E-5A0B-4FAC-ABFD-BA84B103D938

P577

Q33395544-3B481A4F-DDDB-46A9-8AD5-B565A3DF8FED

P698

Q33395544-5B27FF64-F2FD-42CD-BE3C-E211ABDC8AEF

P932

Q33395544-52DBF7BD-1B19-4B1F-BD44-20E014A7D61C

P356

J.LUNGCAN.2011.05.005

P1433

P1476

A phase II study of obatoclax ...... elapsed small cell lung cancer

@en

P2093

Andrew Brown

http://www.w3.org/2001/XMLSchema#string

Lee M Krug

http://www.w3.org/2001/XMLSchema#string

Leonard James

http://www.w3.org/2001/XMLSchema#string

Leslie Tyson

http://www.w3.org/2001/XMLSchema#string

Maria C Pietanza

http://www.w3.org/2001/XMLSchema#string

Michelle S Ginsberg

http://www.w3.org/2001/XMLSchema#string

Naiyer A Rizvi

http://www.w3.org/2001/XMLSchema#string

Naoko Takebe

http://www.w3.org/2001/XMLSchema#string

Paul K Paik

http://www.w3.org/2001/XMLSchema#string

Rosalyn Juergens

http://www.w3.org/2001/XMLSchema#string

P2860

Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines

Cancer statistics, 2009

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

VP-16 and cisplatin as first-line therapy for small-cell lung cancer.

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.

Small cell lung cancer: have we made any progress over the last 25 years?

Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.

A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.

P304

481-485

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LUNGCAN.2011.05.005

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21620511

http://www.w3.org/2001/XMLSchema#string

P932

3715068

http://www.w3.org/2001/XMLSchema#string